Umecrine raises $2.5M to advance trial testing golexanolone for PBC
Umecrine Cognition has raised around $2.5 million to support an ongoing Phase 1b/2a clinical trial testing its investigational therapy golexanolone for cognitive problems and…
Lindsey Shapiro, PhD, Science Writer—
Articles by Lindsey Shapiro
Pemvidutide shows benefit for MASH in Phase 2b clinical trial
Pemvidutide resolved metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease, without worsening liver scarring (fibrosis) for more than half of people…
Diabetes drug dapagliflozin shows benefits for MASH in Phase 3 trial
Daily treatment with the diabetes medication dapagliflozin eased disease severity for people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease,…
30% rise due in primary sclerosing cholangitis prevalence by 2040
The global prevalence of primary sclerosing cholangitis (PSC), or the total number of existing cases, is expected to increase substantially over the next several…
Imdusiran combos lead to functional cure in some cases of hepatitis B
The investigational treatment imdusiran used as part of combination therapy regimens has led to a functional cure for eight people with chronic hepatitis…
AHB-137 effective for chronic hepatitis B: Phase 2b clinical trial
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
New Phase 2 trial data show benefits of elafibranor for PSC
Daily treatment with Ipsen’s elafibranor safely and effectively eases itching, stabilizes liver scarring, and reduces liver damage biomarkers in adults with primary sclerosing…
MET gene mutations could be rare cause of MASLD, MASH
Rare mutations in the MET gene can cause metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, a study found. After…
Surgery eases symptoms of rare skull condition in boy with Alagille
Craniosynostosis — a condition usually identified in infancy where the bones in a baby’s skull join together prematurely — led to elevated pressure in the…
FDA grants fast track status to gene-editing therapy for hepatitis B
The U.S. Food and Drug Administration (FDA) has granted fast track status to PBGENE-HBV, Precision Bioscience’s gene-editing therapy candidate for chronic hepatitis B…